Braeburn develops next generation therapies for opioid use disorder and for chronic pain with individualized dosing regimens and delivery options.
In the Pipeline
CAM2038 is delivered by subcutaneous injection and provides a slow release of the drug over time through a proprietary system known as FluidCrystal®. Braeburn has resubmitted the New Drug Application for CAM2038 weekly and monthly formulations for opioid use disorder and if approved will be marketed in the U.S. under a licensing agreement with Camurus.
Braeburn is also investigating CAM2038 in opioid dependent patients with chronic pain as part of its ongoing pivotal Phase III program.
FluidCrystal® Injection Technology
The proprietary FluidCrystal® delivery system used in the subcutaneous injection of CAM2038 includes a lipid-based liquid with a dissolved active ingredient. Upon injection and contact with fluids in the tissue, the lipid solution transforms into a crystalline gel, which encapsulates the active ingredient, allowing for a slow release of the drug over time.
The FluidCrystal® delivery system provides a few advantages for the final product such as a small overall injection volume which, in turn, allows for the use of a thin 23 gauge needle. Additionally, the product does not require refrigeration.
Braeburn has resubmitted the New Drug Application for CAM2038 and if approved will be marketed in the U.S. under a licensing agreement with Camurus.
Braeburn is committed to supporting independent scientific research and independent medical education for the advancement of medical and scientific understanding in our therapeutic areas of interest.
Please note that Braeburn will not provide grant support for the following:
• Independent Medical Educational Grants directed to individuals
• Grants to support personal travel, travel fellowships or entertainment activities
• Grants for rewards or recognition
Note that no additional requests will be considered for 2018. Please check back again at a later date.